Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

The tumour suppressor gene TP53 is the most frequently mutated gene in cancer. Wild-type
p53 can suppress tumour development by multiple pathways. However, mutation of TP53 …

Therapies that target signalling molecules that are mutated in cancers can often have
substantial short-term effects, but the emergence of resistant cancer cells is a major barrier …

Background The combination of cobimetinib with vemurafenib improves progression-free
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …

T cell–mediated immunotherapies are promising cancer treatments. However, most patients
still fail to respond to these therapies. The molecular determinants of immune resistance are …

Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive
mechanisms that make static interrogation of genomic alterations insufficient to guide …

Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …

The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …

Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAFV600-
mutant melanoma, but acquired drug resistance is almost universal. We sought to identify …